Abstract
Following the recent clinical clearance of an Indian DNA COVID-19 vaccine, India and Africa are potential regions where DNA vaccines may become a major delivery system subject to a range of immunological and regulatory scrutiny. The ongoing COVID pandemic highlights the need to tackle viral variants and expand the number of antigens and assess diverse delivery systems. To address some of these key issues, we have created a Dengue DNA vaccine candidate with the EDIII region as the key antigen given the promise of this segment in not causing ADE, a challenge with this disease. In addition, we have added the NS1 region to broaden the immune response. Following a large Dengue viral sequencing exercise in India, complemented with data from east Africa, our approach was to generate a consensus of four serotypes ED3-NS1 vaccine to explore tackling the issue of diversity. Our In silico structural analysis of EDIII consensus vaccine sequence revealed that epitopes are structurally conserved and immunogenic across HLA diversity. Vaccination of mice with this construct induced pan-serotype neutralizing antibodies and antigen-specific T cell responses. Furthermore, the DNA vaccination confers protection against DENV challenge in AG129 mice. Finally, assaying of intracellular staining for IFN-γ, immunoglobulin IgG2(a/c) /IgG1 ratios as well as immune gene profiling suggested a strong Th1-dominant immune response. Our Dengue DNA platform with a focus on Indo-African sequences offers an approach for assessing cross reactive immunity in animal models and lays the foundation for human vaccine roll out either as a stand-alone or mix and match strategy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by philanthropist Mr. Narayana Murthy, Co-founder of Infosys, NCBS/TIFR, DBT to SK, RGCB (Intramural grant) to ES, and TRC-BIRAC grant to GM. The sponsors of the study had no role in study design, sample collection, data collection, data analysis, data interpretation, or writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethical Clearance Review Boards approved the study of all institutions participating in this study (SJRI- IRB NO:-236/2016, AIIMS, Jodhpur-AIIMS/IEC/2017/49, & AIIMS/IEC/2019-20/939, KIH- IRB NO:07/2018, Ethics/THSTI/2011/2.1; AIIMS: IEC/NP:338/2011). The study was also approved by National Centre for Biological Sciences (NCBS) and Rajiv Gandhi Centre for Biotechnology (RGCB) Institutional Animal Ethics committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Whole Dengue virus genome sequences generated in the study have been deposited in the GenBank. The authors confirm that the data supporting the study findings are available within the manuscript and its supplementary figures and tables. Additional raw data supporting the findings of this study are available from the corresponding authors AS and ES on request.
